TECH Earnings Date: Nov 4, 2026 (Estimated) — Bio-Techne Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is TECH's next earnings date?
Bio-Techne Corporation (TECH) is expected to report Q1 2027 earnings on Wednesday, November 4, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.44 on revenue of $292.6M.
How did TECH do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q4 2026), Bio-Techne Corporation posted EPS of $0.52 versus the $0.52 estimate, a beat of 2.0%. Revenue was $321.2M against a $314.6M estimate. The stock's 1-day post-earnings move was +0.1%.
How much does TECH stock move after earnings?
TECH beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.8% (up or down) in the day after earnings.
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q4 2026 | 0.52 | 0.52 | +1.96% | $321.2M | ✅ Beat | +0.11% | +0.10% | +0.01% |
| 2026-05-06 | Q3 2026 | 0.52 | 0.53 | +1.92% | $311.4M | ✅ Beat | -16.35% | -16.33% | -6.00% |
| 2026-02-04 | Q2 2026 | 0.40 | 0.46 | +15.00% | $295.9M | ✅ Beat | +6.26% | +0.26% | -13.40% |
| 2025-11-05 | Q1 2026 | 0.40 | 0.42 | +5.00% | $286.6M | ✅ Beat | -1.91% | -3.14% | +4.13% |
| 2025-08-06 | Q4 2025 | 0.48 | 0.53 | +10.42% | $317.0M | ✅ Beat | -8.72% | -3.32% | -3.00% |
| 2025-02-05 | Q2 2025 | 0.38 | 0.42 | +10.53% | $297.0M | ✅ Beat | +3.72% | -5.81% | -12.52% |
| 2024-10-30 | Q1 2025 | 0.38 | 0.42 | +10.53% | $289.5M | ✅ Beat | +7.48% | +9.73% | +6.68% |
| 2024-08-07 | Q4 2024 | 0.49 | 0.49 | +0.00% | $306.1M | ➖ Inline | -9.51% | -6.34% | -7.61% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY26 · $298.1M total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| Consumables | 87.5% | $260.7M | +3.1% | $230.7M | $257.8M | $252.9M | $231.6M |
| Instruments | 10.6% | $31.5M | +9.1% | $30.9M | $26.1M | $28.9M | $21.8M |
| Royalty | 2.0% | $5.9M | +6.5% | $8.1M | $5.0M | $5.5M | $5.6M |
By region
Q4 FY26 · $321.2M total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| U S | 51.7% | $166.1M | -5.8% | $159.9M | $181.9M | $176.4M | $155.2M |
| Europe | 25.0% | $80.3M | +14.1% | $70.4M | $66.5M | $70.3M | $65.1M |
| C N | 8.4% | $26.9M | 0.0% | $24.8M | $24.5M | $26.9M | $24.8M |
| APAC, excluding Greater China | 6.9% | $22.1M | +17.0% | $19.0M | $21.2M | $18.9M | $19.1M |
| UNITED KINGDOM | 4.5% | $14.5M | -2.2% | $13.2M | $12.9M | $14.8M | $13.2M |
| Rest Of World | 3.5% | $11.3M | +17.4% | $9.7M | $9.2M | $9.6M | $9.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.